Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. Under the terms of the agreement, Exelixis will pay STORM an upfront fee of $17 million in exchange for licensing two of STORM’s discovery programs targeting RNA modifying enzymes, including ADAR1, as well as provide funding for discovery research activities conducted or managed by STORM. Exelixis will be solely responsible for global development, manufacturing and commercialization activities of any resulting molecules. STORM will be eligible for development, regulatory and commercialization milestones, as well as tiered royalties on the annual net sales of any compounds that are successfully commercialized under the collaboration.

For further information, see PR Newswire (https://www.prnewswire.com/news-releases/exelixis-and-storm-therapeutics-enter-into-exclusive-collaboration-and-license-agreement-to-discover-and-develop-inhibitors-of-novel-rna-modifying-enzymes-301400235.html)

Leave a Reply

Your email address will not be published. Required fields are marked *